share_log

Moderna | 8-K: Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates

Moderna | 8-K：Moderna公布第四季度和2023财年财务业绩并提供业务最新情况

美股sec公告 ·  02/22 06:36
Moomoo AI 已提取核心信息
On February 22, 2024, Moderna, Inc. reported its financial results for the fourth quarter and the full fiscal year of 2023. The company announced a fourth-quarter revenue of $2.8 billion, a decrease from the previous year's $5.1 billion, primarily due to reduced COVID-19 vaccine sales. Despite this, Moderna posted a GAAP net income of $217 million and a diluted EPS of $0.55 for the quarter. For the full year, revenues were $6.8 billion with a GAAP net loss of $(4.7) billion and a diluted EPS of $(12.33), largely impacted by non-cash charges and a tax valuation allowance. Moderna reaffirmed its 2024 product sales forecast of approximately $4 billion and expects regulatory approvals for its RSV vaccine for older adults in the first half of 2024. The company also anticipates key...Show More
On February 22, 2024, Moderna, Inc. reported its financial results for the fourth quarter and the full fiscal year of 2023. The company announced a fourth-quarter revenue of $2.8 billion, a decrease from the previous year's $5.1 billion, primarily due to reduced COVID-19 vaccine sales. Despite this, Moderna posted a GAAP net income of $217 million and a diluted EPS of $0.55 for the quarter. For the full year, revenues were $6.8 billion with a GAAP net loss of $(4.7) billion and a diluted EPS of $(12.33), largely impacted by non-cash charges and a tax valuation allowance. Moderna reaffirmed its 2024 product sales forecast of approximately $4 billion and expects regulatory approvals for its RSV vaccine for older adults in the first half of 2024. The company also anticipates key milestones from its late-stage pipeline this year. The financial results reflect a year of transition as Moderna adapts to the endemic market, with significant pipeline advancements across various sectors and increased COVID-19 market share in the U.S. Moderna's CEO, Stéphane Bancel, emphasized the company's focus on commercial execution and continued investment in the pipeline with financial discipline.
2024年2月22日，Moderna, Inc.公布了其第四季度和2023年整个财年的财务业绩。该公司宣布第四季度收入为28亿美元，较上年的51亿美元有所下降，这主要是由于 COVID-19 疫苗销售减少。尽管如此，Moderna公布的本季度GAAP净收入为2.17亿美元，摊薄后的每股收益为0.55美元。全年收入为68亿美元，GAAP净亏损为47亿美元，摊薄后每股收益为12.33美元，主要受非现金费用和税收估值补贴的影响。Moderna重申了其2024年产品销售额约40亿美元的预测，并预计其老年人呼吸道合胞病毒疫苗将在2024年上半年获得监管部门的批准。该公司还预计，今年其后期产品线将迎来关键里程碑。财务业绩反映了随着 Moderna 适应流行市场而经历的一年过渡期，各行各业的产品线取得了长足的进步，COVID-19 在美国的市场份额也有所增加。Moderna 首席执行官斯特凡·班塞尔强调了公司专注于商业执行，并根据财务纪律继续投资管道。
2024年2月22日，Moderna, Inc.公布了其第四季度和2023年整个财年的财务业绩。该公司宣布第四季度收入为28亿美元，较上年的51亿美元有所下降，这主要是由于 COVID-19 疫苗销售减少。尽管如此，Moderna公布的本季度GAAP净收入为2.17亿美元，摊薄后的每股收益为0.55美元。全年收入为68亿美元，GAAP净亏损为47亿美元，摊薄后每股收益为12.33美元，主要受非现金费用和税收估值补贴的影响。Moderna重申了其2024年产品销售额约40亿美元的预测，并预计其老年人呼吸道合胞病毒疫苗将在2024年上半年获得监管部门的批准。该公司还预计，今年其后期产品线将迎来关键里程碑。财务业绩反映了随着 Moderna 适应流行市场而经历的一年过渡期，各行各业的产品线取得了长足的进步，COVID-19 在美国的市场份额也有所增加。Moderna 首席执行官斯特凡·班塞尔强调了公司专注于商业执行，并根据财务纪律继续投资管道。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息